Bantam Pharmaceutical Starts Clinical Trial for Advanced Cancer Therapy at Princess Margaret Cancer Centre Bantam Pharmaceutical has announced the first patient treatment for BTM-3566 in a pivotal Phase 1 clinical trial at Princess Margaret Cancer Centre, targeting aggressive cancers.

Bantam Pharmaceutical Starts Clinical Trial for Advanced Cancer Therapy at Princess Margaret Cancer Centre #Canada #Toronto #Bantam_Pharmaceutical #BTM-3566 #Princess_Margaret

Bantam Pharmaceutical Set to Showcase Cancer Treatment Progress at ASCO 2025 Annual Meeting Bantam Pharmaceutical announces its acceptance for presentation at ASCO 2025, showcasing its promising cancer treatment, BTM-3566.

Bantam Pharmaceutical Set to Showcase Cancer Treatment Progress at ASCO 2025 Annual Meeting #United_States #Chicago #ASCO_2025 #Bantam_Pharmaceutical #BTM-3566

Bantam Pharmaceutical Unveils Promising Preclinical Results for BTM-3566 at AACR Annual Meeting 2025 Bantam Pharmaceutical presents groundbreaking preclinical data for BTM-3566 at AACR 2025, showcasing solid tumor regression and FAM210B as a key biomarker.

Bantam Pharmaceutical Unveils Promising Preclinical Results for BTM-3566 at AACR Annual Meeting 2025 #United_States #Chicago #Bantam_Pharmaceutical #BTM-3566 #FAM210B

Bantam Pharmaceutical to Showcase Breakthrough Cancer Treatment at AACR 2025 Annual Meeting Bantam Pharmaceutical will present its innovative cancer therapy, BTM-3566, at the AACR Annual Meeting 2025, highlighting significant tumor regression results.

Bantam Pharmaceutical to Showcase Breakthrough Cancer Treatment at AACR 2025 Annual Meeting #USA #Chicago #Bantam_Pharmaceutical #BTM-3566 #AACR_Annual_Meeting

Bantam Pharmaceutical Advances BTM-3566 Trial With Expansion into Canada Bantam Pharmaceutical is advancing its Phase 1 clinical trial for BTM-3566 by expanding into Canada, targeting aggressive B-cell lymphomas.

Bantam Pharmaceutical Advances BTM-3566 Trial With Expansion into Canada #Canada #Clinical_Trial #Research_Triangle_Park #Bantam_Pharmaceutical #BTM-3566

Bantam Pharmaceutical Launches Phase 1 Clinical Trial for New Cancer Treatment at MD Anderson Bantam Pharmaceutical has commenced its Phase 1 clinical trial for BTM-3566 at MD Anderson Cancer Center, targeting B-cell lymphomas. This innovative treatment aims to enhance cancer therapies.

Bantam Pharmaceutical Launches Phase 1 Clinical Trial for New Cancer Treatment at MD Anderson #United_States #MD_Anderson #Research_Triangle_Park #Bantam_Pharmaceutical #BTM-3566